Haseli Sara, Mansoori Bahar, Christensen Diana, Abadi Alireza, Pooyan Atefe, Shomal Zadeh Firoozeh, Mau Brian, Khalili Nastaran, Murphey Mark, Chalian Majid
From the Department of Radiology, Division of Musculoskeletal Imaging and Intervention (S.H., A.P., F.S.Z., M.C.), Department of Radiology, Division of Abdominal Imaging (B.M., D.C., A.A.), and Department of Laboratory Medicine and Pathology (B.M.), University of Washington, UW Radiology-Roosevelt Clinic, 4245 Roosevelt Way NE, Box 354755, Seattle, WA 98105; Cancer Immunology Project, Universal Scientific Education and Research Network, Philadelphia, Pa (N.K.); and Department of Radiologic Pathology, Armed Forces Institute of Pathology, Walter Reed Army Medical Center, Washington, DC (M.M.).
Radiographics. 2023 Aug;43(8):e230005. doi: 10.1148/rg.230005.
Fibroblastic and myofibroblastic tumors are a variable group of neoplasms ranging from benign to malignant. These lesions may affect patients of any age group but are more frequently encountered in the pediatric population. Patient clinical presentation depends on the location, growth pattern, adjacent soft-tissue involvement, and pathologic behavior of these neoplasms. In the 2020 update to the World Health Organization (WHO) classification system, these tumors are classified on the basis of their distinct biologic behavior, histomorphologic characteristics, and molecular profiles into four tumor categories: benign (eg, fibrous hamartoma of infancy, nodular fasciitis, proliferative fasciitis, fibroma of the tendon sheath, calcifying aponeurotic fibroma); intermediate, locally aggressive (eg, desmoid fibromatosis); intermediate, rarely metastasizing (eg, dermatofibrosarcoma protuberans, myxoinflammatory fibroblastic sarcoma, low-grade myofibroblastic sarcoma, infantile fibrosarcoma); and malignant (eg, sclerosing epithelioid fibrosarcomas; low-grade fibromyxoid sarcoma; myxofibrosarcoma; fibrosarcoma, not otherwise specified). Detection of various components of solid tumors at imaging can help in prediction of the presence of corresponding histopathologic variations, thus influencing diagnosis, prognosis, and treatment planning. For example, lesions with a greater myxoid matrix or necrotic components tend to show higher signal intensity on T2-weighted MR images, whereas lesions with hypercellularity and dense internal collagen content display low signal intensity. In addition, understanding the radiologic-pathologic correlation of soft-tissue tumors can help to increase the accuracy of percutaneous biopsy and allow unnecessary interventions to be avoided. RSNA, 2023 Quiz questions for this article are available in the supplemental material.
纤维母细胞及肌纤维母细胞肿瘤是一组具有多种生物学行为的肿瘤,从良性到恶性。这些病变可发生于任何年龄段的患者,但在儿童中更为常见。患者的临床表现取决于肿瘤的位置、生长方式、邻近软组织受累情况以及病理行为。在 2020 年世界卫生组织(WHO)分类系统更新中,这些肿瘤根据其独特的生物学行为、组织形态学特征和分子谱,分为 4 个肿瘤类别:良性(如婴儿纤维性错构瘤、结节性筋膜炎、增生性筋膜炎、腱鞘纤维瘤、钙化腱膜纤维瘤);局部侵袭性中间型(如硬纤维瘤);罕见转移的中间型(如隆突性皮肤纤维肉瘤、黏液炎症性纤维母细胞肉瘤、低度恶性肌纤维母细胞肉瘤、婴儿纤维肉瘤);恶性(如硬化性上皮样纤维肉瘤、低度黏液纤维黏液肉瘤、黏液纤维肉瘤、未分化纤维肉瘤)。在影像学检查中检测到实体肿瘤的各种成分有助于预测相应的组织病理学变化,从而影响诊断、预后和治疗计划。例如,黏液基质或坏死成分较多的病变在 T2 加权磁共振成像上往往显示出更高的信号强度,而细胞密度较高和内部胶原含量丰富的病变则显示出低信号强度。此外,了解软组织肿瘤的影像学-病理学相关性有助于提高经皮活检的准确性,并避免不必要的干预。RSNA,2023 本文的问答测验可在补充材料中获取。